Shares of Oramed are down 73% or $7.92 in pre-market trading at $2.87. Last night, the company announced that the top-line results from its Phase 3 clinical trial comparing the efficacy of ORMD-0801 to placebo in patients with Type 2 Diabetes at 26 weeks did not meet its primary endpoint. The stock has also been downgraded to Hold at Canaccord this morning.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ORMP:
- Oramed downgraded to Hold at Canaccord after ORMD-0801 discontinued
- Oramed downgraded to Hold from Buy at Canaccord
- Oramed Crashes after Disappointing Topline Results
- Oramed’s results from phase 3 trial of ORMD-0801 did not meet primary endpoint
- Oramed granted combination therapy patent for treating diabetes
